Complex Regulation of the Cyclin-dependent Kinase Inhibitor P27kip1 in Thyroid Cancer Cells by the PI3K/AKT Pathway: Regulation of P27kip1 Expression and Localization

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2005 Mar 4

PMID 15743786

Citations 43

Authors

Maria Letizia Motti

Daniela Califano

Giancarlo Troncone

Carmela De Marco

Ilenia Migliaccio

Emiliano Palmieri

Luciano Pezzullo

Lucio Palombini

Alfredo Fusco

Giuseppe Viglietto

Affiliations

Soon will be listed here.

Abstract

Functional inactivation of the tumor suppressor p27(kip1) in human cancer occurs either through loss of expression or through phosphorylation-dependent cytoplasmic sequestration. Here we demonstrate that dysregulation of the PI3K/AKT pathway is important in thyroid carcinogenesis and that p27(kip1) is a key target of the growth-regulatory activity exerted by this pathway in thyroid cancer cells. Using specific PI3K inhibitors (LY294002, wortmannin, and PTEN) and a dominant active AKT construct (myrAKT), we demonstrated that the PI3K/AKT pathway controlled thyroid cell proliferation by regulating the expression and subcellular localization of p27. Results obtained with phospho-specific antibodies and with transfection of nonphosphorylable p27(kip1) mutant constructs demonstrated that PI3K/AKT-dependent regulation of p27(kip1) mislocalization in thyroid cancer cells occurred via phosphorylation of p27(kip1) at T157 and T198 (but not at S10 or T187). Finally, we evaluated whether these results were applicable to human tumors. Analysis of 100 thyroid carcinomas indicated that p27(kip1) phosphorylation at T157/T198 and cytoplasmic mislocalization were preferentially associated with activation of the PI3K/AKT pathway. Thus the PI3/AKT pathway and its effector p27(kip1) play major roles in thyroid carcinogenesis.

Citing Articles

Hydrogen sulfide donor activates AKT-eNOS signaling and promotes lymphatic vessel formation.

Aithabathula R, Pervaiz N, Kathuria I, Swanson M, Singh U, Kumar S PLoS One. 2023; 18(10):e0292663.

PMID: 37883422 PMC: 10602273. DOI: 10.1371/journal.pone.0292663.

Mechanistic Insights of Thyroid Cancer Progression.

Leandro-Garcia L, Landa I Endocrinology. 2023; 164(9).

PMID: 37503738 PMC: 10403681. DOI: 10.1210/endocr/bqad118.

LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the PI3K/AKT pathway.

Xu D, Guo L, Zhang S, Hou Q Gland Surg. 2022; 11(9):1518-1528.

PMID: 36221286 PMC: 9547712. DOI: 10.21037/gs-22-452.

The AMPK/p27 Pathway as a Novel Target to Promote Autophagy and Resilience in Aged Cells.

McKay L, White J Cells. 2021; 10(6).

PMID: 34201101 PMC: 8229180. DOI: 10.3390/cells10061430.

Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid Cancer.

Li Q, Jiang S, Feng T, Zhu T, Qian B Onco Targets Ther. 2021; 14:3119-3131.

PMID: 34012269 PMC: 8127002. DOI: 10.2147/OTT.S301127.

References

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K . Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999; 18(5):1223-34. PMC: 1171213. DOI: 10.1093/emboj/18.5.1223. View

Kimura T, Dumont J, Fusco A, Golstein J . Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. Eur J Endocrinol. 1999; 140(1):94-103. DOI: 10.1530/eje.0.1400094. View

Sgambato A, Cittadini A, Faraglia B, Weinstein I . Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol. 2000; 183(1):18-27. DOI: 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S. View

Polyak K, Kato J, Solomon M, Sherr C, Massague J, Roberts J . p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994; 8(1):9-22. DOI: 10.1101/gad.8.1.9. View

Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G . PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene. 2000; 19(28):3146-55. DOI: 10.1038/sj.onc.1203633. View

Saito J, Kohn A, Roth R, Noguchi Y, Tatsumo I, Hirai A . Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid. 2001; 11(4):339-51. DOI: 10.1089/10507250152039073. View

Gesbert F, Sellers W, Signoretti S, Loda M, Griffin J . BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000; 275(50):39223-30. DOI: 10.1074/jbc.M007291200. View

Ortega S, Malumbres M, Barbacid M . Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002; 1602(1):73-87. DOI: 10.1016/s0304-419x(02)00037-9. View

10.

Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta G, Pagano M . p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 2001; 20(23):6672-82. PMC: 125773. DOI: 10.1093/emboj/20.23.6672. View

11.

Vitagliano D, Carlomagno F, Motti M, Viglietto G, Nikiforov Y, Nikiforova M . Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res. 2004; 64(11):3823-9. DOI: 10.1158/0008-5472.CAN-03-3918. View

12.

Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V . Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet. 2004; 41(3):161-70. PMC: 1735712. DOI: 10.1136/jmg.2003.015339. View

13.

Coulonval K, Vandeput F, Stein R, Kozma S, Lamy F, Dumont J . Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J. 2000; 348 Pt 2:351-8. PMC: 1221073. View

14.

Blain S, Massague J . Breast cancer banishes p27 from nucleus. Nat Med. 2002; 8(10):1076-8. DOI: 10.1038/nm1002-1076. View

15.

Gimm O, Perren A, Weng L, Marsh D, Yeh J, Ziebold U . Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000; 156(5):1693-700. PMC: 1876937. DOI: 10.1016/S0002-9440(10)65040-7. View

16.

Eng C . Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol. 1998; 12(3):701-10. DOI: 10.3892/ijo.12.3.701. View

17.

Pagano M, Tam S, Theodoras A, Del Sal G, Chau V, Yew P . Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995; 269(5224):682-5. DOI: 10.1126/science.7624798. View

18.

Catzavelos C, Bhattacharya N, Ung Y, Wilson J, Roncari L, Sandhu C . Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997; 3(2):227-30. DOI: 10.1038/nm0297-227. View

19.

Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F . Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest. 1999; 104(7):865-74. PMC: 408550. DOI: 10.1172/JCI6443. View

20.

Blagosklonny M . Are p27 and p21 cytoplasmic oncoproteins?. Cell Cycle. 2003; 1(6):391-3. DOI: 10.4161/cc.1.6.262. View